A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

Project: Research

Project Details

Project Description

NMA/ERM Reference Number: 63271
SSA Review Reference: SSA/63271/MonH-2020-216746(v1)
Monash Health Reference: RES-20-0000-254A
Effective start/end date23/06/2022/06/25


  • clinical trade
  • phase 1 study
  • treatment effiacy
  • lung cancer
  • pancreatic cancer
  • colorectal cancer treatment